Summary of Product Characteristic - Physiotens 0.2 mg, Physiotens 0.3 mg, Physiotens 0.4 mg (Moxonidinum) (in Polish), The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products Home Page, Poland. At http://www.urpl.gov.pl/ rejestr//Physiotens02_ 03_04.pdf. Accessed 19 June 2008.
Summary of Product Characteristic - Physiotens 0.2 mg, Physiotens 0.3 mg, Physiotens 0.4 mg (Moxonidinum) (in Polish), The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products Home Page, Poland. At http://www.urpl.gov.pl/ rejestr//Physiotens02_ 03_04.pdf. Accessed 19 June 2008.
2
0029787839
Aspects of tolerability of centrally acting antihypertensive drugs
Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol 1996; 27:49-54.
Safety and tolerabilility of moxonidine in the treatment of hypertension
Schachter M, Luszick J, Jäger B, Verboom C, Söhlke E. Safety and tolerabilility of moxonidine in the treatment of hypertension. Drug Saf 1998; 19:191-203.